P reeclampsia (PE) is a serious disorder that affects 5% to 8% of pregnancies 1 and causes 15% to 20% of maternal mortalities and morbidities in developed countries.
P reeclampsia (PE) is a serious disorder that affects 5% to 8% of pregnancies 1 and causes 15% to 20% of maternal mortalities and morbidities in developed countries. 2 Despite serious global effect, the primary method of PE diagnosis continues to rely on presentation of maternal symptoms, including hypertension and proteinuria, after 20 weeks of gestation. However, present diagnostic approaches are inadequate to identify patients likely to experience adverse outcomes because 10% to 15% of women who experience hemolysis, elevated liver enzymes, and low platelet levels (HELLP syndrome) and 20% to 25% who progress to eclampsia do not present with either hypertension or proteinuria. 3 Consequently, there remains a need for noninvasive diagnostics that can accurately and reliably identify patients who develop PE and those at risk for adverse outcomes.
Diagnostic development efforts have focused on the identification of protein biomarkers with unique presentation in PE. Multiple proteins exhibit altered serum levels in PE and have been pursued as candidate biomarkers and therapeutic targets, including soluble vascular endothelial growth factor receptor (sFlt-1), placental growth factor (PlGF), 4 soluble endoglin, 5 placental protein 13, 6 and angiotensin II type 1 receptor (AT 1 ) autoantibodies (AT 1 -AAs). 7 In particular, much effort has focused on evaluating the diagnostic use of the ratio of elevated sFlt-1 to lowered PlGF levels or the PlGF level alone. 8 These biomarkers have yielded high diagnostic accuracy for detecting early-onset PE and predicting adverse outcomes. 9 However, these biomarkers are less effective after 34 weeks' gestation, 8 the period when 90% of PE cases present. 1 Finally, they do not enable accurate prediction of PE during the first trimester 10 because sFlt-1 levels only become significantly altered ≈5 weeks before PE onset. 4 Therefore, despite the use of these biomarkers for early-onset PE detection, additional biomarkers are needed.
Circulating antibodies represent a rich source for additional biomarker discovery, and several observations link the immune system to PE pathogenesis. Most prominently, patients with PE have been found to produce agonistic immunoglobulin (Ig) AT 1 -AAs 7 as early as 18 weeks' gestation. 11 Several in vivo and in vitro studies have demonstrated a potential pathological role Abstract-The presence of maternal autoantibodies has been previously associated with preeclampsia, although the composition of the antibody repertoire in preeclampsia has not been well characterized. Given this, we applied a bacterial display peptide library to identify peptides that preferentially react with plasma antibodies from patients with preeclampsia (n=15) versus healthy-outcome pregnancies (n=18). Screening using fluorescence-activated cell sorting identified 38 peptides that preferentially bind to antibodies from individuals with preeclampsia. These preeclampsiaspecific peptides possessed similar motifs of R G / S G / -WW G / S , RWW G / S , or WGWGXX R / K distinct from the angiotensin II type 1 receptor epitope AFHYESQ. Seven library-isolated peptides and a cell surface-displayed angiotensin II type 1 receptor epitope were used to construct a diagnostic algorithm with a training set of 18 new preeclamptic and 22 healthy-outcome samples from geographically distinct cohorts. Cross-validation within the training group resulted in averaged areas underneath a receiver operating characteristic curve of 0.78 and 0.72 with and without the known receptor epitope, respectively. In a small validation set (12 preeclamptic; 8 healthy), the algorithm consisting only of libraryisolated peptides correctly classified 10 preeclamptic and 6 healthy samples using a predefined cutoff that achieved 61% sensitivity (95% confidence interval, 36%-83%) at 95% specificity (95% confidence interval, 77%-100%) in training set (n=40) cross-validation. Our results indicate that antibodies with specificities other than anti-angiotensin II type 1 receptor are prevalent in preeclampsia patients and may be useful as diagnostic biomarkers. (Hypertension.
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for these antibodies. Injection of AT 1 -AAs or total IgG isolated from patients with PE into pregnant mice induced the hallmark PE symptoms (hypertension, proteinuria, and increased sFlt-1 12 and fetal growth restriction), 13 whereas coinjection with an antibody-blocking peptide epitope attenuated these effects. Interestingly, placental ischemia-stimulated AT 1 -AAs similarly contribute to hypertension in an independent PE rat model.
14 AT 1 -AAs increase complement protein C3 deposition in the placenta and kidney of pregnant mice, 15 while mutations within complement system regulatory proteins seem to be a risk factor for PE. 16 Complement activation has been further implicated in PE with increased C3 deposits in placental vessels from a transgenic PE rat model, and supernatant from PE placental explants stimulate C3 expression in rat vascular smooth muscle cells. 17 Furthermore, isolated CD19 + CD5 + B cells are elevated in PE and produce AT 1 -AAs in culture on addition of PE serum. 18 At the same time, individuals with PE exhibit significantly reduced levels of CD4 +
CD25
+ regulatory T cells, 19 a finding consistent with increased autoantibody production. 20 Collectively, these previous studies indicate that immunologic alterations are a conserved feature in PE.
Despite a demonstrated role of AT 1 -AAs in the pathology of PE, their efficacy for PE diagnosis has not been established. Existing assays for AT 1 -AAs that rely on cardiomyocyte beat rate 7 or a luciferase reporter 21 lack throughput and are unsuitable for point-of-care diagnostics. More importantly, AT 1 -AA prevalence varies significantly in different studies (70% 22 -95% 21 ), and AT 1 -AAs are not specific to PE because they have been observed in individuals with healthy-outcome pregnancy (HOP), 22 chronic hypertension, 23 and renal allograft rejection. 24 Given these problems, we investigated whether additional PE-specific antibodies exist that could serve as biomarker(s) for PE diagnosis and further implicate a pathophysiological role for an altered immune system. To simultaneously identify antibody biomarkers and peptide reagents for their detection, we screened a bacterial display peptide library 25 against antibodies enriched from the plasma of individuals with PE and HOPs. Our results demonstrate the existence of PE-specific plasma antibodies, other than AT 1 -AAs, that may be useful for PE diagnosis.
Materials and Methods

Patient Samples
Whole blood samples were obtained from pregnant women as aliquots of samples taken for routine blood work during clinical assessments at the Santa Barbara Cottage Hospital (cohort 1). The study was approved by the Santa Barbara Cottage Hospital review board. To qualify as affected with PE, subjects fulfilled ≥2 of the following criteria: (1) 2 documented blood pressures (BPs) with readings >140/90 mm Hg ≥4 hours apart, with documented normal BPs in the first half of the pregnancy; (2) proteinuria as defined by ≥30 mg/dL on a spot urine check, ≥1+ dipstick reading, or ≥300 mg/24 hours; (3) central nervous system symptoms (visual disturbances or unremitting headaches); (4) epigastric pain associated with elevated liver enzymes unrelated to other abdominal pathology; or (5) thrombocytopenia with platelet counts <100 000 U/mL. This ensured that PE samples met the American College for Obstetricians and Gynecologists criteria for mild or severe PE diagnosis. Pre-existing hypertension and lupus patients were excluded from cohort 1. Samples were divided into a discovery set (n=33) for initial peptide identification and a training set (n=20) for testing diagnostic ability of isolated peptides.
Additional deidentified samples provided from University of Texas Medical School at Houston (cohort 2) were used in either the training set (n=20) or a validation set (n=20). These PE samples were diagnosed by clinical assessments based on the National High Blood Pressure Education Program Working Group Report.
This study did not distinguish between early-and late-onset PE and did not discriminate based on parity. Therefore, these cohorts represent a mix of presentation times and parities. All subjects provided informed consent, and samples were collected according to institutional guidelines. Blood samples for both cohorts were obtained near the time of delivery. In cohort 1, BPs were recorded at the time of presentation, whereas cohort 2 recorded maximum BP before delivery. In addition, while cohort 1 mainly used the spot urine check, cohort 2 diagnosis used 24-hour analysis and the dipstick test (n=7).
Bacterial Display and Library Screening
The AT 1 epitope AFHYESQ was displayed on Escherichia coli MC1061 26 with flanking glycines as a fusion to the N terminus of the eCPX (enhanced circularly permuted OmpX) scaffold 27 along with a C-terminal peptide tag (P2x) that binds a fluorescent reporter (YPet-Mona) of scaffold expression. 28 A 15-mer random peptide library displayed on the N terminus of the eCPX scaffold was screened for peptides binding to PE-specific antibodies. Library screening used antibody fractions in PBS (0.1% BSA) prepared by ammonium sulfate precipitation of patient plasma and depleted of E. coli-binding antibodies. Magnetic selection enriched for peptides that bind pooled PE (n=9) antibodies (5 μmol/L total concentration) labeled with the FluoReporter Mini-Biotin-XX Protein Labeling Kit (Invitrogen) while outcompeting an unlabeled pool of HOP (n=12) antibodies (5 μmol/L total). To favor cross-reactivity, 2 pools of PE antibodies with distinct fluorophores were prepared: group 1 (n=4) labeled with Alexa Fluor 488 (Invitrogen; green) and group 2 (n=5) biotinylated (red) to enable detection with streptavidin-conjugated R-phycoerythrin (Invitrogen). Cells were coincubated with excess unlabeled HOP antibodies and labeled PE antibodies, and those cells exhibiting both red and green fluorescence were recovered by fluorescence-activated cell sorting ( Figure 1A ). Peptides with specificity for PE antibodies were favored in separate sorts using a PE antibody pool (n=9) labeled with Alexa Fluor 488 and a biotinylated HOP antibody (n=12) pool. After recovering nonfluorescent cells that did not capture HOP antibodies, cells exhibiting green, not red, fluorescence were collected after labeling with PE and HOP antibody pools followed by streptavidin-conjugated R-phycoerythrin ( Figure 1B ). Screening continued with a set of new PE and HOP (n=6 each) samples to enhance PE cross-reactivity and specificity.
Peptide Sequence Analysis and Downselection
Plasmid DNA from ≈200 bacterial colonies was sequenced from the final sorting round, from which 83 unique sequences were identified using Geneious. Three additional peptides that demonstrated PE reactivity and specificity in an earlier screening round were incorporated into the motifs identified by inspection ( Figure 1C) . The binding activity, or fold fluorescence over a negative control (empty scaffold), of each library peptide and the AT 1 epitope clone was measured in duplicate with discovery set PE and HOP (n=6 each) pools. After incubation with each antibody pool (1 μmol/L), cells were labeled using biotinylated antihuman IgA + IgG + IgM (Jackson ImmunoResearch), followed by streptavidin-conjugated R-phycoerythrin. On average, peptides exhibited 1.4-fold increased PE antibody-binding activity compared with HOP. Therefore, peptides demonstrating 50% higher PE reactivity over HOP (1.5-fold) were selected as the most specific and ranked according to the PE activity quotient defined as the PE-binding activity multiplied by the ratio of PE activity to HOP (ie, dynamic range).
Patient Antibody Reactivity Assays
The AT 1 epitope and 7 downselected peptides were assayed in duplicate against biotinylated antibodies ( 
Statistical Analysis
A subset (20 cohort 1 and 20 randomly selected cohort 2 samples) of the 60 samples not used for discovery was used to train a classification algorithm followed by testing with a validation set (20 remaining cohort 2 samples) to verify peptide panel diagnostic accuracy. To reduce overfitting to the training set, an Adaptive Boosting (AdaBoost) classification algorithm, which applies the algorithm successively to reweighted versions of the training set, 29 was implemented through the ada package in R 30 using a 4-split tree. Diagnostic algorithms were generated with and without the AT 1 epitope included in the peptide panel. Three trials of 10-fold cross-validation across a combined set from both cohorts (n=40) yielded each sample's averaged probability for PE classification, which was used to perform receiver operating characteristic (ROC) curve analysis with the pROC R package and assess algorithm accuracy. Additional algorithms were trained using cohort 1 or 2 separately with or without the AT 1 epitope. Subsequently, the performance of the 6 algorithms was assessed by generating ROC curves and determining the PE, HOP, and overall classification accuracy at a 0.5 probability cutoff in the final validation set.
Separately, ROC analysis was performed with Prism 4 software (GraphPad Software Inc) for each library-isolated peptide across the entire set of 60 validation samples based on binding activity. ROC analysis of the AT 1 epitope was performed on the same 60 samples for comparison with library-isolated peptides followed by analysis across the entire set of 45 PE and 48 HOP samples described in this study. Excluding Figures 3 and 4 , data are presented as mean±SEM. Statistical significance using the Student t test or Mann-Whitney U test and Spearman correlation were assessed with Prism 4 software. For all analyses, P<0.05 was considered significant.
Results
Identification of Peptides Binding to Plasma Antibodies From Patients With PE
The 45 PE samples used in this study reflect the heterogeneity of PE presentation including early-and late-onset PE cases and atypical severe cases without proteinuria (Table 1; Table S1 in the online-only Data Supplement). To identify PE-specific antibody-detecting peptide reagents within this diverse group, a bacterial display library was screened for peptides that bind Figure 1 . A 2-color screening methodology isolated a pool of preeclampsia (PE)-specific antibody-detecting peptides, enabling further characterization of individual peptides. A, After coincubating a bacterial display peptide library with 2 distinctly labeled pools of PE (red or green fluorophore) and an unlabeled pool of healthyoutcome pregnancy (HOP) antibodies enriched from plasma, cells expressing peptides that bind antibodies present in both groups with PE were isolated. B, Subsequently, the library was coincubated with a labeled HOP antibody pool (red) and a PE pool (green). Bacteria exhibiting only green fluorescence were isolated, ensuring disease specificity. C, Finally, sequence analysis of the enriched pool identified unique peptides for motif characterization, and individual peptide PE-and HOP-binding activities (fluorescent intensity) were assessed. antibodies present in multiple patients with PE but not HOP subjects. This screening strategy used fluorescence-activated cell sorting to quantitatively measure the enrichment of PE antibody-binding peptides from 7% to 87% ( Figure S1A and S1B) of the bacterial cell population and reduction of HOP antibody-reactive peptides ( Figure S1C and S1D). From this enriched pool, DNA sequencing identified 83 unique peptides, enabling further characterization of each member alongside 3 peptides from an earlier screening round. None of the libraryisolated peptides were similar to the known AT 1 receptor epitope AFHYESQ, but several different motifs were identified (Table  S2) . Three motifs (a-1 to a-3) were similar, and 4 additional motifs were distinct. The library peptide consensus sequence motifs were not sufficiently strong to enable identification of antigens that elicited the antibodies. Roughly 48 candidate autoantigens were identified by rank-ordering proteins with high similarity scores obtained using blastp and ScanProsite searches (Table S3) ; however, a much larger number of nonself proteins in the entire database also carried these motifs.
In total, 38 of 86 novel peptides and the AT 1 epitope exhibited an average 1.5-fold increased PE-binding activity compared with HOP, and these peptides were ranked according to their PE-specific antibody-binding activity (ie, activity quotient; Figure S2 ). The most PE-specific and reactive peptides exhibited an activity quotient of ≥6, and the most highly represented motifs among these peptides were determined ( Figure 2 ). The greatest fraction (10/22) of peptides with a high PE activity quotient represented the a-1 motif (R G / S G / -WW G / S ), which was also comprised of the greatest number of unique peptides. Individual peptides from these motifs did not exhibit reduced PE antibody binding after depletion with the AT 1 epitope AFHYESQ ( Figure S3 ), indicating that library-isolated peptides did not mimic the AT 1 epitope.
Peptides Demonstrate Diagnostic Ability on a Validation Set
To assess the diagnostic efficacy of these PE-specific peptides, 7 library-isolated peptides with PE activity quotients >6 and the AT 1 epitope were tested for reactivity against 30 new PE and 30 HOP patients. Together, the panel of library-isolated peptides performed well, achieving 100% accuracy within the cohort 1 validation set ( Figure S4 ), whereas the AT 1 epitope alone accurately classified 6 of 10 PE and 9 of 10 HOP in cohort 1. Cross-validation trials across the combined training set (n=40) using library-isolated peptides with and without the AT 1 epitope yielded averaged areas under the curve (AUC) of 0.78 and 0.72, respectively (Figure 3 ), achieving 61% (95% confidence interval, 36%-83%) sensitivity at 95% (95% confidence interval, 77%-100%) specificity (Table S4) . Comparatively, the AT 1 epitope alone demonstrated an AUC of 0.65 in this set of 40 samples and at 61% sensitivity exhibited 55% (95% confidence interval, 32%-76%) specificity. Next, the classification accuracy of algorithms trained using cohort 1, cohort 2, or the combined set with and without the AT 1 epitope was assessed using an external validation set (20 remaining cohort 2 samples). The ROC curves of all 6 predictive algorithms revealed that use of samples from both cohorts in training resulted in the highest AUC, especially when including the AT 1 epitope (0.83; Figure S5 ). The algorithm trained using only the library peptides with the combined set attained a similar AUC (0.78), and both algorithms achieved comparable overall accuracy, 75% and 80%, respectively, at the prescribed cutoff. Although the algorithm including the AT 1 epitope yielded only 1 false-positive, it misclassified 2 more PE samples than the algorithm using only library peptides (Table 2) . Finally, classification accuracy was not significantly different when analysis was restricted to cases of PE (n=19) identified strictly with proteinuria and no pre-existing hypertension. The array algorithm excluding the AT 1 epitope correctly detected 12 (63%) subjects of this PE subgroup, compared with 70% in the full, more heterogeneous group (n=30). In addition to evaluating overall diagnostic performance, the antibody-detecting peptide algorithm was assessed for adverse outcome detection use. Because of the inclusion criteria used in this study, 6 of 30 patients with PE used in training and validation exhibited severe symptoms, such as central nervous system disturbances, thrombocytopenia, and elevated liver enzymes, without proteinuria. Importantly, the antibodydetecting peptide panel identified 5 of these 6 atypical patients with PE. Furthermore, the peptide panel detected 5 of 6 nonproteinuric patients with PE that delivered before 37 weeks' gestation (n=18; Table 3 ). This could help stratify patients requiring more timely delivery thereby complementing severe symptom detection. Overall, combining clinical criteria of high BP and proteinuria along with the antibody-detecting peptide panel achieved the highest sensitivity for severe symptoms and early delivery.
Statistical Analysis of Individual Peptide Performance
Individual peptides constituting the panel exhibited differing diagnostic efficacy. The AT 1 epitope exhibited significantly (P<0.05) higher PE antibody binding when evaluated across the entire sample set (45 PE and 48 HOP; Figure S6 ). Here, the AT 1 epitope detected binding antibodies in 78% of PE and 44% of HOP, resulting in an AUC of 0.66. However, binding of antibodies from subjects with PE to the AT 1 epitope was not significantly increased in the validation set composed of 60 samples. In contrast, 5 library-isolated peptides exhibited significantly (P<0.05) higher reactivity with PE samples than with HOP samples ( Figure 4A) . In addition, library-isolated peptides achieved comparable or higher AUCs than the AT 1 epitope. Peptides cross-reacted with multiple PE patient antibodies, and antibodies from PE that reacted strongly with 1 peptide tended to bind multiple peptides ( Figure 4B) . Similarly, HOP antibodies that reacted with 1 peptide also tended to bind multiple peptides including the AT 1 epitope. Nevertheless, the 7-member panel exhibited stronger diagnostic efficacy than any individual peptide. Interestingly, peptide-binding activity, especially peptide 36 (r s =−0.62), inversely correlated with PE patient platelet count in this set ( Figure S7 ). Summing the standardized binding activity of the 7 library-isolated peptides and AT 1 epitope yielded the overall correlation (r s =−0.56) with platelet count. Analysis of other patient characteristics (ie, BP or proteinuria) did not reveal strong correlations with peptide standardized reactivity.
Discussion
In this study, we present evidence that PE is associated with a distinctive signature of antibody-binding specificities. This signature was represented in a PE antibody-detecting peptide panel composed of multiple epitope specificities. One such specificity corresponds to a 7-mer epitope of the AT 1 receptor. 7 The pathobiological significance of these AT 1 -AAs is now supported by multiple independent studies, demonstrating their ability to increase BP, proteinuria, and sFlt-1 12 and complement deposition. 15 Despite this increased complement deposition in the placenta and kidney of pregnant mice, blocking the AT 1 receptor did not fully reduce deposition to HOP levels, leaving open the possibility that other antibodies could play a role in PE pathology. The pursuit for additional PE antibody markers has identified an association between PE and antibodies binding various autoantigens, including β1, β2, and α1 adrenoreceptors, 31 cardiolipin, 32 and prothrombin. 33 However, the use of unbiased discovery approaches to characterize the complete antibody repertoire has not been described. Furthermore, the antigens responsible for eliciting these autoantibodies have not been determined, and their binding epitope specificities remain uncharacterized. Using an unbiased antibody repertoire analysis method, we observed a unique epitope reactivity pattern and used representative peptides to develop a PE antibody-detecting panel for diagnosis. In spite of the strong evidence for AT 1 -AAs in PE, we did not identify peptides with similarity to the AT 1 epitope AFHYESQ. This result might be explained by an insufficient antibody affinity or titer or the high frequency of AT 1 -AA in HOP subjects (used for subtraction) in this and previous studies 11, 22 and overall increased activity over nonpregnant normotensive subjects. 34 Although the mechanism responsible for the PE antibody signature is unclear, the reduced prevalence of T-regulatory cells in PE 19 may contribute to elevated autoantibody production. In addition, the observation that several nonself proteins also carry these motifs raises the possibility that the antibodies may originally be responding to an environmental trigger as previously proposed for AT 1 -AAs. 22 Regardless of the production mechanism, this study supports an altered immune response in PE pathophysiology by verifying the presence of PE-specific antibodies in addition to AT 1 -AAs that could be useful for diagnosis.
Despite the demonstrated role of AT 1 -AAs in PE and potential for use in diagnosis and guiding therapy, their detection has proven exceptionally difficult. Current detection techniques rely on complex biological function assays 7, 21 that are unlikely to be effective for point-of-care diagnosis. To address this problem, we developed a unique binding assay for AT 1 -AA detection using the 7-mer epitope displayed in a high-avidity format on the bacterial cell surface. One recent study demonstrated higher AT 1 -AA titers in patients with PE (n=13) over HOPs (n=30) using the 27-aa second extracellular loop in an ELISA 34 ; however, here the cell-displayed 7-mer was sufficient to detect epitope-specific antibodies in 78% of patients with PE and 44% of HOP (45 PE and 48 HOP). Thus, AT 1 -AA detection can be performed with the 7-mer and does not require the entire loop. Assays based on the minimal 7-mer may be important for developing therapeutics designed to block this antibody specificity 12 and differentiate this from specificities present in other diseases such as renal allograft rejection. 24 For comparison, a biological function assay identified AT 1 -AAs in ≈70% of patients with PE and 20% of HOPs 22 in addition to 62% of HOPs with abnormal perfusion. 11 The percentage of HOP subjects in our study that experienced abnormal perfusion during pregnancy is not known because the test is not part of routine practice. Regardless, these results demonstrate the use of an epitope-specific binding assay for AT 1 -AA detection in patients with PE, for which researchers have previously relied on complex biological function assays.
The 7-member PE antibody-detecting panel demonstrated a potential use for detecting PE cases that is comparable with current protein biomarkers. The peptide panel exhibited 100% accuracy in the validation set from cohort 1 and maintained strong accuracy (80%) despite the inclusion of a second cohort from a distinct geographic location, which affects a population's antibody repertoire. 35 Despite this effect, the panel exhibited comparable diagnostic efficacy to biomarkers in clinical development, such as sFlt-1 and PlGF. Studies evaluating these markers have primarily focused on early-onset PE in which they show the strongest accuracy; however, the accuracy drops in late-onset (≥34 weeks) PE. 36 Commercially available diagnostic kits for the sFlt-1/PlGf ratio and PlGF alone exhibited 59% sensitivity at 100% specificity and 77% sensitivity at 95% specificity, respectively, across all gestational onsets. 8 Similarly, this study did not discriminate between early-and late-onset, and the antibody-detecting peptide panel achieved 61% sensitivity at 95% specificity within the cross-validated training set. It remains to be determined whether the PE-specific peptide panel can perform similarly in larger cohorts. Nevertheless, our results indicate that a PE antibody-detecting peptide panel can effectively discriminate PE and HOP samples and demonstrate that patients with PE possess a distinctive antibody repertoire signature. This PE-specific antibody signature was associated with an increased detection of adverse outcomes. A substantial percentage of patients who develop HELLP syndrome (10%-15%) or eclampsia (20%-25%) are not detected by the current clinical criteria of hypertension and proteinuria. 3 Thus, there exists an unmet need to identify those at risk of developing these adverse outcomes. The antibody-detecting peptide panel outperformed (81%) clinical criteria (63%) in detecting patients (n=16) with severe PE characterized by symptoms of central nervous system disturbances, elevated liver enzymes, and thrombocytopenia, suggesting that this antibody signature is more strongly associated with these severe PE symptoms. Furthermore, peptide-binding activity inversely correlated with platelet levels. Continued investigation of this association may link a pathophysiological role for these antibodies to these severe symptoms.
Perspectives
Here, we demonstrated the existence of antibody biomarkers present in patients with PE distinct from known AT 1 -AAs that achieve strong diagnostic accuracy (80%) for PE. Thus, our results provide supporting evidence for an altered immune response in PE. Identifying the antigen(s) mimicked by our library-isolated peptides may enable characterization of the antibody's contribution to PE pathogenesis while elucidating potential therapeutic targets. Furthermore, the use of the whole or partial antigen(s) mimicked by library peptides may further increase sensitivity/specificity of the assay. In addition, the ability to detect PE early in pregnancy before clinical presentation would aid patient management. A time-course study using the PE antibody-detecting peptides described here could identify when these antibodies first present to assess their potential use in the early diagnosis of PE. Finally, because this methodology does not require purified antibodies, screening can be conducted using unprocessed, diluted plasma to identify peptide diagnostic reagents that bind PE-specific antibodies without the additional purification step. 
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ONLINE SUPPLEMENT CHARACTERIZATION OF ANTIBODY SPECIFICITIES ASSOCIATED WITH PRE-ECLAMPSIA
Bacterial display and library screening
All cultures for screening and analysis were subcultured (1:50), grown to an OD 600 of 0.4-0.6, and induced for one hour with 0.04% arabinose. Streptavidin (SA) binding peptides were removed from the library using MyOne SA-coated magnetic beads. Following magnetic enrichment, the first FACS round utilized 2.5 μmol/L from each PE group and five-fold excess HOP pool, while the subsequent two rounds lowered the PE concentration to 1 μmol/L and increased normal antibodies to 10 and 15-fold excess, respectively. To favor PE specificity, nonfluorescent cells were collected after incubating the library with 1 μmol/L pooled, biotinylated HOP Ig followed by SA-PE labeling. Two screening rounds isolated peptides that only bind the pooled, Alexa 488 labeled PE Ig (1 μmol/L) and not the biotinylated HOP Ig (1 μmol/L). The library population was further sorted against 6 each new PE and HOP samples in a similar fashion. After completing rounds six and seven for cross-reactivity sorting with 1 μmol/L of each disease group and unlabeled 15-fold excess and 20-fold excess of HOP, respectively, two specificity rounds were performed to select peptides binding only disease samples as described above. Another negative sorting round enriched bacteria displaying peptides that did not bind the biotinylated HOP Ig pool. Finally, three additional rounds of peptide enrichment were performed towards binding pooled PE (1 μmol/L) but not HOP (2.5 or 1 μmol/L) Ig, using the HOP concentration that showed the highest binding activity.
Testing for mimicry of the known AT 1 epitope
To determine whether library-isolated peptides were mimicking the known AT 1 epitope, E. coli displaying the AFHYESQ epitope were used to deplete binding Ig, and reactivity with the indicated library-isolated clones was measured. The PE Ig pool (1 µmol/L) used for downselection was incubated with AT 1 epitope expressing cells (1x10 8 cells/µL). Cells were centrifuged, and the AT 1 -AA depleted supernatant was retained and assayed against libraryisolated peptides and the AT 1 epitope clone.
Identifying candidate antigens
The motifs identified by inspection were used to perform protein database searches using NCBI blastp and ScanProsite. After applying a similarity scoring metric, the top 80% of extracellular protein hits from each search were compiled into a list of candidate antigens with the corresponding fragment. The respective motif name and consensus sequence is shown. Names indicated correspond to peptides with 1.5-fold higher PE activity than HOP Figure S1. Library screening resulted in a PE cross-reactive and specific peptide population. Cross-reactivity sorts enriched for peptides that simultaneously bind antibodies present in two PE groups separately labeled with a red or green fluorophore while competing with an unlabeled HOP pool. A. Prior to FACS, only 7% of the peptide library population showed cross-reactive binding; however, B. after nine rounds of sorting, 87% bound antibodies present in two PE groups. Further sorting rounds focused on enhancing PE specificity using a red labeled HOP pool and green PE pool. C. While initially 53% of the PE cross-reactive population also bound antibodies in the HOP pool, D. the final library population demonstrated high specificity with 78% binding only to the PE antibody pool and 8% also binding the HOP antibody pool. Gates were set according to single color and negative control populations. Figure S3 . Comparison of antibody reactivity before and after AT 1 -AA depletion. The reactivity of each of the library-isolated peptides analyzed was not significantly decreased by AT 1 -AA depletion. However, the significant loss in binding activity to the AT 1 epitope confirmed appropriate depletion of AT 1 -AAs from the sample (n=6). 
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